Date updated:01-05-2007
One hundred years ago, Dr. Alois Alzheimer identified the ailment that bears his name. Scientists are now decoding the disease and testing drugs that could delay and maybe even cure Alzheimer's. Here are the public companies who are beind these drugs designed to treat, delay or prevent Alzheimer's.
According to a recent BusinessWeek article, "there are currently 4.5 million Alzheimer's patients in the U.S., and the direct and indirect costs of caring for them total more than $100 billion a year, making Alzheimer's the third most expensive illness after heart disease and cancer. Yet the federal government budgeted only $645 million for Alzheimer's research for 2007, $7 million less than the prior year. In contrast, $2.6 billion was allocated for research into HIV/AIDS, which afflicts one million Americans."

-
NRMX
Neurochem Inc - $2.00
- 0.00%
- $N/A
The drug Alzhemed is being produced by Neurochem. It prevents the accumulation of amyloid, a toxic protein that destroys brain cells in Alzheimer's victims. It's in Phase 3 late stage testing. The data on Alzhemed have been promising but scant. In a 2002 study it stabilized the disease in nine patients over six months, but the small sample left plenty of specialists skeptical. A clinical trial of the drug will wrap up in January, with results expected in the spring.

-
MYGN
Myriad Genetics - $60.18
- -0.20%
- $60.31
The drug Flurizan is being produced by Myriad Genetics. It inhibits the production of amyloid. It's in Phase 3 of testing with results expected next summer.

-
NHPI.OB
Neuro-hitech Inc - $0.34
- 0.00%
- $N/A
The drug Huperzine is being produced by Neuro-Hitech. It strengthens memory formation and may protect brain cells from damage caused by Alzheimer's. It's in Phase 2 mid-stage testing.

-
MEMY
Memory Pharmaceut - $0.3202
- -5.82%
- $0.3148
The drug MEM1003 is being produced by Memory Pharmaceuticals. It evens out the irregularities in brain levels of calcium - one of the first manifestations of Alzheimer's. It's in Phase 2 of testing.

-
WYE
Wyeth - $47.10
- -0.88%
- $47.70
The drug AAB-001 is being produced by Wyeth and Elan. It's a monoclonal antibody that seeks out and removes amyloid in the brain. It's in Phase 2 of testing.

-
LLY
Lilly Eli Co - $47.91
- -0.97%
- $48.50
The drug LY450139 is being produced by Eli Lilly. It blocks an enzyme that snips off amyloid fragments, thus reducing the production of amyloid. It's in Phase 2 of testing.

-
ELN
Elan Cp Plc Adr - $34.66
- +5.86%
- $32.48
The drug ACC-101 is being produced by Elan and Wyeth. The vaccine prompts the body's immune system to attack and remove amyloid in the brain. It's in Phase 1 (early safety tests)

-
DNA
Genentech Inc - $81.82
- +0.81%
- $81.00
Nearly 60 drugs designed to modify the disease are in clinical trials. One is from AC Immune of Switzerland who recently struck a deal with biotech power player Genentech Inc. (DNA ). While known for its cancer treatments, Genentech just announced plans to invest $300 million for the rights to AC Immune's drug.
- Top Professional Portfolios
- 1. T. Rowe Price New Era ...
- 2. Profunds UltraSector O...
- 3. The Children's Investm...
- 4. U.S. Global Investors ...
- 5. Jennison Utility A (PR...
- show all
- Top Do-It-Yourself Portfolios
- » Insane
- » wanda hulbert Portfolio 1
- » Mad Growth
- » divy
- » thevaluemaster Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » 10 Short Squeezes
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- show all
Small-Cap Growth Manager: Barron's spoke with Jim Oberweis, manager of the $10-million Oberweis Mid-Cap Fund (OBMDX) and president of Oberweis Asset Management. Some of the...
Stocks in India soared for the second day in a row Friday, as short sellers raced to cover positions, after crude oil prices continued to slide lower and inflation data cam...
I have been watching E3 2008 for a couple of reasons this year. The first is because I am a casual gamer, and E3 is the granddaddy of all video gaming conventions -- and le...
7-18-08 The clouds have parted -- at least momentarily. Wall Street rallied on Wednesday and closed at a three-month high. And then we had some follow-through yesterda...
A. bounce? yes, but id fade it after it.
they need more time to cool off. in
fact, if youre a commodity bull, you
want them to stall out here.
general rule, the longer the base, the
longer the breakout
A. Investing resources for creating
wealth!
Pet Supplies & Training needs. Global
shipping.
Finest blue nose pitbulls in its breed!
Environment News, Information,
resources!
Please visit: Coffee-Advice.com
Dog & Puppy resources, news, articles,
and more.
Got acne? Cures, Treatments, articles,
and more.
Restore that classic Pontiac musclecar.
Click here.
Shop your favorite stores from across
the country!
Google it here!
Latest News & Technology headlines from
around the globe.
This list consists of stocks that are down 10% or more in the last year but may be poised to surprise us on the upside going forward. The basis for the list is as follows: ... more
Analyst Downgrades for 07-17-08 more
These are some of the stocks mentioned today on TheStreet.com TV. Click the URL below each stock to watch the videos. more






Comments not available